The Medicines and Healthcare products Regulatory Agency has reaffirmed that the UK’s hepatitis B vaccination programme for babies remains safe, effective, and unchanged following continued national and international safety monitoring. The statement confirms that universal infant vaccination, in place since 2017, continues to meet strict standards for safety, quality and effectiveness.
The regulator also confirmed that higher-risk newborns will continue to receive additional protection at birth, alongside routine screening of all pregnant women. The announcement is intended to reassure parents that existing NHS vaccination schedules remain fully supported by current evidence.
Regulatory Confirmation on Infant Hepatitis B Vaccination
The MHRA issued the statement as part of its ongoing role in overseeing the safety of medicines and vaccines used across the UK. It reiterated that all vaccines authorised for use must undergo rigorous independent assessment before approval, including evaluation of manufacturing quality and clinical effectiveness. This regulatory process applies to all childhood vaccines currently in routine use.
The agency confirmed that hepatitis B vaccination for babies continues to demonstrate a strong safety profile based on long-term surveillance. This monitoring draws on UK healthcare data, international safety reporting systems and independent scientific review.
How the Current UK Vaccination Schedule Works
Hepatitis B protection for babies in the UK is delivered through the long-established universal childhood immunisation programme. The schedule is guided by recommendations from the Joint Committee on Vaccination and Immunisation and supported by NHS clinical guidance.
Routine Vaccination from Eight Weeks
For the majority of babies, hepatitis B protection is provided as part of the standard 6-in-1 vaccine. This is administered at eight, 12 and 16 weeks of age as part of the routine infant immunisation programme. These doses form the basis of long-term protection against the virus for children across the UK.
Additional Protection for High-Risk Newborns
All pregnant women in the UK are routinely screened for hepatitis B during early pregnancy. If a mother is found to be infected, her baby is classed as being at higher risk of contracting the virus. In these cases, the newborn receives a separate hepatitis B vaccine dose within 24 hours of birth, followed by additional doses during the first year.
Routine and High-Risk Vaccination Pathways
| General infant schedule | 6-in-1 vaccine at 8, 12 and 16 weeks |
| High-risk newborns | Separate birth dose within 24 hours plus follow-up doses |
| Maternal screening | Routine blood test early in pregnancy |
Ongoing Vaccine Safety Monitoring
The MHRA confirmed that safety surveillance continues after vaccines are introduced into widespread use. This process is supported by multiple data streams designed to detect and assess any potential safety signals as early as possible.
Monitoring includes analysis of large healthcare datasets within the UK, collaboration with international regulatory partners, and continuous review by independent scientific experts. This allows the regulator to update guidance quickly if new evidence emerges.
The Yellow Card Reporting System
Members of the public and healthcare professionals are encouraged to report any suspected side effects from vaccines through the Yellow Card scheme. These reports are assessed by safety specialists and contribute to wider surveillance activity. The MHRA has confirmed that this reporting mechanism remains a central part of its post-approval monitoring process.
Core Safety Oversight Measures
| Independent pre-approval assessment | Safety, quality and effectiveness checks before authorisation |
| Post-approval surveillance | Ongoing monitoring using UK and international data |
| Public reporting | Yellow Card scheme for suspected side effects |
Guidance for Parents and Maternity Care
The regulator’s message to parents is that there is no change to existing NHS vaccination requirements. Babies whose mothers test negative for hepatitis B will continue to receive routine protection through the standard infant schedule.
For families where a mother is found to carry the virus, the established birth-dose pathway remains in place to reduce the risk of transmission. For most parents, this process forms part of standard maternity care and routine antenatal blood testing.
- Attend all routine antenatal screening appointments
- Follow the standard NHS infant vaccination timetable
- Report any suspected side effects through the Yellow Card scheme
Addressing Safety and Autism Concerns
The MHRA restated that multiple large international studies, including registry-based and sibling-controlled research, have found no evidence linking childhood vaccines with autism. This position reflects a long-standing international scientific consensus.
The agency also confirmed that if new safety evidence were to emerge, official guidance would be updated promptly for both healthcare professionals and the public.
- No evidence of a link between vaccines and autism
- Continuous scientific review of safety data
- Rapid regulatory response if new risks arise
Stakeholder Comments
Ministerial Comments
Dr Alison Cave, Chief Safety Officer at the MHRA said;
“Patient safety is our top priority, which is why all vaccines authorised for use in the UK undergo rigorous assessment for safety, quality and effectiveness.”
“Extensive safety monitoring in the UK and internationally continues to show that the benefits of these vaccinations outweigh any risks.”
International and Public Health Context
The MHRA’s position aligns with guidance from the NHS, the World Health Organization and other global public-health bodies, which support childhood vaccination as the most effective way to prevent serious infectious diseases.
While debates have emerged in some countries about scaling back universal hepatitis B vaccination at birth, UK policy remains unchanged. National authorities have confirmed that existing protections for infants will continue based on the current evidence base.
Bottom Line
For UK parents, the message from regulators is that the established hepatitis B vaccination programme for babies remains fully in place and backed by long-term safety monitoring. Routine screening during pregnancy and early vaccination continue to provide layered protection for newborns and infants.
The MHRA has confirmed that surveillance will remain active, ensuring that national guidance continues to reflect the best available scientific evidence.
Sources: Medicines and Healthcare products Regulatory Agency, December 2025; NHS Childhood Immunisation Programme guidance; Joint Committee on Vaccination and Immunisation recommendations.
Prepared by Ivan Alexander Golden, Founder of THX News™, an independent news organisation delivering timely insights from global official sources. Combines AI-analysed research with human-edited accuracy and context.
